There’s a new emphasis on bringing innovative medicines to the Japanese market – how can your biopharma take the next steps? Join Endpoints in a discussion with senior Japanese leaders, and hear firsthand perspectives on the regulatory and pricing dynamics behind one of the world’s top pharma markets. This is part of Endpoints’ ongoing series with PMDA officials — Japan’s regulatory body — and experienced Japanese pharma execs.

Developing a biopharma drug and want to enter Japan? Please join our discussion.